NeoGenomics (NASDAQ:NEO) Rating Reiterated by Benchmark

Benchmark reaffirmed their buy rating on shares of NeoGenomics (NASDAQ:NEO) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $18.00 price target on the medical research company’s stock.

Several other research analysts have also recently weighed in on NEO. Stephens reaffirmed an overweight rating and set a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Needham & Company LLC reaffirmed a buy rating and set a $19.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $19.89.

NeoGenomics Trading Down 1.0 %

NASDAQ:NEO opened at $14.50 on Tuesday. NeoGenomics has a 1 year low of $11.03 and a 1 year high of $21.22. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -22.27 and a beta of 1.19. The business has a fifty day moving average of $16.06 and a 200-day moving average of $14.94. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.93 and a current ratio of 2.01.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. During the same quarter in the prior year, the business posted ($0.09) earnings per share. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. Equities analysts predict that NeoGenomics will post -0.22 earnings per share for the current year.

Institutional Trading of NeoGenomics

A number of large investors have recently bought and sold shares of the stock. First Light Asset Management LLC lifted its stake in NeoGenomics by 29.6% in the fourth quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after buying an additional 897,843 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in NeoGenomics in the first quarter valued at about $680,000. Edgestream Partners L.P. acquired a new position in NeoGenomics in the first quarter valued at about $1,894,000. Jennison Associates LLC lifted its stake in NeoGenomics by 77.8% in the first quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock valued at $16,532,000 after buying an additional 460,071 shares during the period. Finally, Bellevue Group AG acquired a new position in NeoGenomics in the first quarter valued at about $14,872,000. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.